Radionuclide Therapy
Saul Hertz, MD, and the birth of radionuclide therapy
... targeted radionuclide ther- apy to demonstrate the fundamental principles of both molecular nuclear medicine and ...for radionuclide therapy, with the recent introductions of 223 Ra dichloride for ...
7
Radiation-Induced Second Cancer Risk Estimates From Radionuclide Therapy
... of radionuclide therapy in the clinical setting is expected to increase significantly over the next ...five radionuclide therapy patients was ...
5
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
... Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients with metastasized ...
12
Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
... to therapy. Peptide receptor radionuclide therapy was performed according to the joint IAEA, EANM and SNMMI practical guidance and consisted of a total of four individual cycles performed every 12 ...
6
Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy
... radionuclide therapy of EGFR-positive cancer and the use of US-induced cavitation to enhance its delivery to breast cancer tumour models was investigated. The liposomal formulation has shown promise in ...
15
Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review
... targeted radionuclide therapy; ECT: emission computed tomography; Ho-166-PLLA-MS: Ho-166 labeled poly (L-lactic acid) microsphere; RE: radio-embolization; SIRT: selective internal radiation therapy; ...
15
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
... Background: Dosimetry in radionuclide therapy has the potential to allow for a treatment tailored to the individual patient. One therapeutic radiopharmaceutical where patient-specific dosimetry is feasible ...
17
<p>Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights</p>
... grade 2 panNETs. CAPTEM when compared to single-agent TEM improved progression-free survival (PFS) 22.7 months (mo) vs 14.4 mo (p=0.023), overall survival (OS) not reached vs 38 mo (p=0.012), and overall response rate ...
11
Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
... Non-functional pancreatic neuroendocrine tumours (NETs) can present with advanced local or distant (metastatic) disease limiting the possibility of surgical cure. Several treatment options have been used in experimental ...
5
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
... receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA- Tyr3-octreotate ...the ...
7
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
... Background: Peptide receptor radionuclide therapy (PRRT) is applied in patients with advanced neuroendocrine tumors. Co-infused amino acids (AA) should prevent nephrotoxicity. The aims of this study were to ...
8
Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
... Pb etc.), which can be introduced during product analysis and post-processing, is lower compared to 177 Lu. This results in the potentially stronger interference from environmen- tal impurities during radiolabeling of ...
16
Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
... anti-cancer therapy based on uPA/uPAR system, it is desirable to develop non-invasive imaging methods to visualize and quantify uPAR expression in ...and radionuclide therapy ...
9
Dosimetry in clinical radionuclide therapy: the devil is in the detail.
... of equivalent doses to all organs, each adjusted with the appropriate tissue weighting factor; taking in account the sensitivity of the organ to radiation) expressed in mSv for the whole body. The 3 kinds of radiation ...
5
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
... receptor radionuclide therapy is administered to patients on an inpatient and outpatient basis for the treatment of well- differentiated, metastatic neuroendocrine ...
12
A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy
... targeted radionuclide therapy justify all the efforts to develop in vivo α -particle nanogenerators and to enable a wider application of 230 U, 225 Ac, 224 Ra and 223 ...the radionuclide is localized ...
26
Monte Carlo Simulation in Radionuclide Therapy Dosimetry
... simulation therapy with beta emitters (β-) applied on the tumor cells ...specific radionuclide, tumor mass and ...of radionuclide and optimal calculation of administered activity in the ...
6
Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases
... Targeted radionuclide therapy (TRT) allows precise delivery of systemically administered radioactivity to disseminated cancer ...the radionuclide [10]. An added advantage of this therapy is ...
12
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
... Despite initial responsiveness to both chemotherapy and radiotherapy, small cell lung cancer (SCLC) commonly relapses within months. Although neuroendocrine characteristics may be difficult to demonstrate in individual ...
8
Developmental trends in targeted radionuclide therapy of neuroendocrine tumors
... Survival and response after peptide receptor radionuclide therapy with [ 90 Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl[r] ...
6